UBS set a €120.00 ($142.86) price objective on Merck KGaA (FRA:MRK) in a research note issued to investors on Wednesday. The brokerage currently has a buy rating on the healthcare company’s stock.

A number of other analysts have also commented on MRK. Commerzbank set a €109.00 ($129.76) target price on Merck KGaA and gave the company a neutral rating in a research report on Wednesday, August 9th. set a €94.00 ($111.90) target price on Merck KGaA and gave the company a neutral rating in a research report on Wednesday, August 9th. Goldman Sachs Group set a €105.00 ($125.00) target price on Merck KGaA and gave the company a neutral rating in a research report on Thursday, August 17th. DZ Bank reaffirmed a neutral rating on shares of Merck KGaA in a research report on Thursday, August 17th. Finally, Berenberg Bank set a €109.00 ($129.76) target price on Merck KGaA and gave the company a neutral rating in a research report on Friday, August 18th. Twelve analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company has an average rating of Hold and a consensus target price of €107.81 ($128.34).

Shares of Merck KGaA (FRA MRK) traded down €0.19 ($0.23) during trading on Wednesday, reaching €87.90 ($104.64). The company had a trading volume of 598,106 shares. Merck KGaA has a twelve month low of €87.33 ($103.96) and a twelve month high of €115.00 ($136.90).

WARNING: “Merck KGaA (MRK) Given a €120.00 Price Target at UBS” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/merck-kgaa-mrk-given-a-120-00-price-target-at-ubs/1749681.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.